Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Monitored issues related to FDA approval of breakthrough therapies. Cures 2.0 and issues related to FDA.
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Duration: April 1, 2016
to
December 31, 2021
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations , Government Issues , Taxation/Internal Revenue Code
Spending: about $1,320,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stacey Hughes
U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
Don Nickles
U.S. Senator
Mary Beth Savary Taylor
Joint Economic Committee, General Counsel, U.S. Senator Connie Mack, Legislative Assistant
Emily Porter
Ofce of Spkr(Rep.Boehner),Asst to Spkr,Policy;Ofce of Min.Leader(Rep.Boehner),Plcy Adv;Ofce of the Maj. Ldr(Rep. Boehner),Plcy Adv;Cmte Ed & the Wrkfrc(Rep.Boehner),Coaltions Dir. for Educ Plcy; Rep.Trent Franks,Sr.Leg.Asst; Rep.Tom Tancredo,Leg.Asst
Katherine Raab
House Cmte on Energy and Commerce, Prof. Staff; Congressman Mary Bono, Leg. Asst.; Congressman Elton Gallegly, Leg. Asst.; Congressman Michael Bilirakis, Leg. Asst.; Congressman Michael Bilirakis, Leg. Corr.; Congressman Michael Bilirakis, Staff Asst
Rachel Jones Hensler
U.S. Senate Budget Committee, Tax Policy Dir.; Office of U.S. Senator Fred Thompson, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Correspondent
Greg D'Angelo
White House Office of Management and Budget, Associate Director of Health Programs;
Senate Committee on the Budget (Sen. Gregg, Sen. Sessions, and Sen. Enzi), Professional Staff Member.
Brett Baker
U.S. Senate Committee on Finance (Senators Crapo, Grassley, and Hatch)-Deputy Health Policy Director; Health Policy Dir.; Senior Policy Advsr; Policy Advisor. U.S. House of Representatives Committee on Ways and Means (Reps. Camp and Ryan) Prof. Staff
Stephanie Badger
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
THE NICKLES GROUP, LLC terminated an engagement in which they represented bluebird bio on Jan. 20, 2022.
Original Filing: 301337177.xml
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Monitored issues related to FDA approval of breakthrough therapies. Cures 2.0 and issues related to FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308156.xml
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Monitored issues related to FDA approval of breakthrough therapies. Cures 2.0 and issues related to FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2021
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301286710.xml
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Monitored issues related to FDA approval of breakthrough therapies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Monitored FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution.
Agencies Lobbied
U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2021
In Q1, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301258892.xml
Lobbying Issues
Issues related to value based payment over time. Issues related to rulemaking supporting VBP arrangements. Monitored issues related to P.L. 117-2, the American Rescue Plan, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Monitored issues related to FDA approval of breakthrough therapies. Monitored P.L. 117-2, the American Rescue Plan.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Monitored FY'21 Budget Resolution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to value-based payment over time. Monitored issues related to P.L. 117-2, the American Rescue Plan.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $50,000. The report was filed on Jan. 21, 2021.
Original Filing: 301245009.xml
Lobbying Issues
S. 2543 Prescription Drug Pricing Act and issues related to value based payment over time; H.R. 5882 Gene Therapy Payment Act; H.R. 3935, the Protecting Patients Transportation to Care Act; issues related to the Notice of Proposed rulemaking supporting VBP Arrangement; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021; monitored issues related to the Most Favored Nation (MFN) rule.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to FDA approval of breakthrough therapies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2020
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221829.xml
Lobbying Issues
S. 2543 Prescription Drug Pricing Act and issues related to value based payment over time; H.R. 5882 Gene Therapy Payment Act; H.R. 3935, the Protecting Patients Transportation to Care Act; issues related to the Notice of Proposed rulemaking supporting VBP Arrangement; issues related to the Executive Order on Lowering Drug Prices by Putting America First.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on July 17, 2020.
Original Filing: 301191001.xml
Lobbying Issues
S. 2543 Prescription Drug Pricing Act and issues related to value based payment over time; H.R. 5882 Gene Therapy Payment Act; H.R. 3935, the Protecting Patients Transportation to Care Act; issues related to the Notice of Proposed rulemaking supporting VBP Arrangements.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on April 17, 2020.
Original Filing: 301171143.xml
Lobbying Issues
Issues related to drug pricing including S. 2543 Prescription Drug pricing Act and issues related to value based payment over time; H.R. 5882 the GENE Therapy Payment Act; H.R. 3 Elijah E. Cummings lower drug costs act; issues related to Medicaid Best Price and AMP reporting. Issues related to H.R. 3935, the Protecting Patients Transportation to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124973.xml
Lobbying Issues
Issues related to the Patient Affordability, Value and Efficacy Act (PAVE); issues related to H.R. 2296, the METRIC Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitored issues related to drug pricing; S. 2543, Prescription Drug Pricing Reduction Act of 2019 and issues related to value-based payment; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2019
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068798.xml
Lobbying Issues
Issues related to the Patient Affordability, Value and Efficacy Act (PAVE); issues related to H.R. 2296, the METRIC Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitored issues related to drug pricing; S. 2543, Prescription Drug Pricing Reduction Act of 2019 and issues related to value-based payment; issues related to H.R. 2507, Newborn Screening Saves Lives Reauthorization Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2019
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301055370.xml
Lobbying Issues
Monitored issues related to drug pricing and transparency; issues related to gene editing and gene therapy; issues related to value based arrangements; issues related to the Patient Affordability, Value and Efficacy Act (PAVE); issues related to H.R. 2296, FAIR Drug Pricing Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH) Health & Human Services - Dept of (HHS)
Lobbying Issues
Monitored issues related to drug pricing; issues related to value-based pricing; monitored issues related to Medicaid nonemergency medical transportation; monitored issues related to H.R. 1839, Medicaid Services Investment and Accountability Act of 2019; issues related to H.R. 2507, Newborn Screening Saves Lives Reauthorization Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2019
In Q1, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on April 19, 2019.
Original Filing: 301031037.xml
Lobbying Issues
Monitored issues related to drug pricing; issues related to gene editing and gene therapy; issues related to value based arrangements; issues related to the Patient Affordability, Value and Efficacy Act (PAVE)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH) Health & Human Services - Dept of (HHS)
Lobbying Issues
Monitored issues related to drug pricing; issues related to value-based pricing; monitored issues related to Medicaid nonemergency medical transportation; monitored issues related to H.R. 1839, Medicaid Services Investment and Accountability Act of 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Monitored issues related to the conference report accompanying H.J. Res 31.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Jan. 18, 2019.
Original Filing: 301008026.xml
Lobbying Issues
Issues related to drug pricing; issues related to gene editing and gene therapy; H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017; issues related to RMAT designation; issues related to value based arrangements.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH) Health & Human Services - Dept of (HHS)
Lobbying Issues
Monitored issues related to drug pricing; issues related to value-based pricing; monitored issues related to Medicaid nonemergency medical transportation. H.R. 3325, Advancing Care for Exceptional Kids Act and S. 2415, Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
3rd Quarter, 2018
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996866.xml
Lobbying Issues
Issues related to drug pricing; issues related to gene editing and gene therapy; H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017; issues related to RMAT designation; issues related to value based arrangements.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH)
Lobbying Issues
Monitored issues related to drug pricing; issues related to value-based pricing; monitored issues related to Medicaid nonemergency medical transportation. H.R. 3325, Advancing Care for Exceptional Kids Act and S. 2415, Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
2nd Quarter, 2018
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300973084.xml
Lobbying Issues
Issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH)
Lobbying Issues
Monitored issues related to drug pricing; issues related to value-based pricing; monitored issues related to Medicaid nonemergency medical transportation. Monitored S. 2415, Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2018
In Q1, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956684.xml
Lobbying Issues
Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH)
Lobbying Issues
H.R. 1892, Bipartisan Budget Act of 2018 and issues related to Medicare reimbursement for prescription drugs; monitored H.R. 1625, Consolidated Appropriations Act of 2018 and issues related to drug pricing; issue related to value-based pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
4th Quarter, 2017
In Q4, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300937120.xml
Lobbying Issues
Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored issues concerning value based contracting.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid and CHIP as it relates to rare pediatric diseases.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1370, An Act to amend the Homeland Security Act of 2002, as it relates to further additional appropriations for 2018 and CHIP and PAYGO.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1, The Tax Cut and Jobs Act, as it relates to the orphan drug tax credit.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
THE NICKLES GROUP, LLC amended a lobbying report for representation of bluebird bio in Q32017 on Oct. 19, 2017.
Original Filing: 300910452.xml
Lobbying Issues
Issues related to novel therapies for rare pediatric populations; H.R. 1628, The American Health Care Act of 2017 including the Better Care Reconciliation Act and the Graham Cassidy amendment; monitored issues related to S.204, the Trickett Wendler Right to Try Act of 2017; monitored issues related to the consideration of S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid and CHIP as it relates to rare pediatric diseases. H.R. 1628, The American Health Care Act of 2017 including the Better Care Reconciliation Act and the Graham Cassidy amendment and issues related to Medicaid and high risk populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910065.xml
Lobbying Issues
Issues related to novel therapies for rare pediatric populations; H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment; monitored issues related to S.204, the Trickett Wendler Right to Try Act of 2017; monitored issues related to the consideration of S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid and CHIP as it relates to rare pediatric diseases. H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment and issues related to Medicaid and high risk populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on July 19, 2017.
Original Filing: 300891499.xml
Lobbying Issues
Issues related to novel therapies for rare pediatric populations; H.R. 1628, The American Health Care Act of 2017; issues related to Medicaid and high risk populations; monitored issues related to S.204, the Trickett Wendler Right to Try Act of 2017; monitored issues related to the consideration of S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Issues related to Medicaid and CHIP as it relates to rare pediatric diseases. H.R. 1628, The American Health Care Act of 2017 and issues related to Medicaid and high risk populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
1st Quarter, 2017
In Q1, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on April 19, 2017.
Original Filing: 300871019.xml
Lobbying Issues
Issues related to the implementation of 21st century cures; issues related to novel therapies for rare pediatric populations; H.R. 1628, The American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid and CHIP as it relates to rare pediatric diseases. Monitored H.R. 1628, The American Health Care Act of 2017 and issues related to Medicaid and high risk populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. Con. Res. 3, FY '17 Budget Resolution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848792.xml
Lobbying Issues
Monitored issues related to Pediatric Review Vouchers; S. 2689 the REGROW Act and H.R. 34, The 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on Oct. 20, 2016.
Original Filing: 300835286.xml
Lobbying Issues
Monitored issues related to Pediatric Review Vouchers; 21cc & Innovation Initiative; and S. 2689 the REGROW Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, THE NICKLES GROUP, LLC lobbied for bluebird bio , earning $60,000. The report was filed on July 18, 2016.
Original Filing: 300811261.xml
Lobbying Issues
Issues related to Pediatric Priority Review Vouchers; monitored 21st CC & Innovation Initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate